The tweet was deleted by the author.
But we saved everything 🙂.
AbbVie submits EMA application for subcutaneous Crohns induction after stock ends session down 1.1%
AbbVie said it had submitted an application to the European Medicines Agency for subcutaneous induction of one of its medicines in Crohns disease on August 21, 2026. The stock is down 1.1% on the day at $262.87.
ABBV price prediction
Current price:
$295.03
0.5400
0.18%
Closed
11/13
Daily range
293.73
297.20
297.20
Weekly range
289.62
300.31
300.31
Loading...
Highlights
- AbbVie has submitted an application to the European Medicines Agency for subcutaneous induction of SKYRIZI in adult Crohns disease.
- 96 of 125 analysts rate AbbVie stock a buy, with a median price target of $280, 6.5% above current levels.
- AbbVie stock is down 1.1% on the day at $262.87.
AbbVie announced on August 21, 2026 that it submitted an application to the European Medicines Agency (EMA) for subcutaneous induction therapy in adults with moderately to severely active Crohns disease. The application seeks approval for SKYRIZI (risankizumab) in this indication, according to PR Newswire. If approved, this would provide adult Crohns disease patients an additional induction treatment option beyond intravenous administration.
View post on X Loading...
Chart structure stays bullish as shares gap lower and test support
The session opened with a gap down from the previous close of $265.79 to $264.09. Shares of AbbVie remain above the MA-20, MA-50, and MA-200, supporting a bullish daily chart structure for now. CCI at 86.8 is nearing overbought territory, which is an early sign that further upside may be limited even as the price holds higher. The nearest support is the weekly low at $260.31.
Upside odds hold as traders watch for a close above resistance
To gauge whether the recent regulatory developments are being reflected in the price, traders should look for a close above $266.9 to show buyers are willing to follow through, or a drop below $260.31 to indicate that the move is being faded. The session began with a gap down, opening at $264.09 compared to the previous close of $265.79. Even with an emerging move lower over the past week that is not yet confirmed, the upside probability over the next five trading days is 77% with a downside probability of 23%, and AbbVie is expected to trade between $259.92 and $265.81. On the weekly chart the longer-term picture stays firmly constructive.
Earlier, analysts noted that AbbVie's bullish technical momentum and ongoing strategic initiatives positioned the stock for potential further gains. The latest regulatory advance in Europe adds a new dimension to the outlook, with traders now watching for a sustained move outside the $259.92 to $265.81 range to confirm the next directional shift.
This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Subscribe to TU news
Did you like the article?
Top News
Top 5 companies for you
United States
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
Live News
